19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways

19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways

Effective postoperative pain management has evolved from reactive, intermittent opioid monotherapy into proactive, mechanistic multimodal analgesia integrated within Enhanced Recovery After Surgery (ERAS) pathways. Unrelieved acute surgical pain is not merely distressing to the patient; it triggers a profound neuroendocrine stress response (accelerating catabolism, tachycardia, myocardial oxygen consumption, hypercoagulability, and immunosuppression) and drives neuroplastic remodeling that can transition into debilitating chronic postsurgical pain (CPSP).

---

1. Neurobiology of Nociceptive Pain and Sensitization

Nociception is the physiological neural process of encoding noxious stimuli, progressing through four distinct phases:

+------------------------------------------------------------------------------------------------------+
|                              THE FOUR PHASES OF THE NOCICEPTIVE PATHWAY                               |
|                                                                                                      |
|  1. TRANSDUCTION     Primary nociceptors (A-delta & C fibers) convert noxious thermal, mechanical,   |
|                      or chemical stimuli into action potentials via TRPV1, ASIC, Nav1.7/1.8/1.9.     |
|                      Inflammatory soup: Bradykinin, PGE2, Substance P, H+, Cytokines.                |
|                                          |                                                           |
|                                          v                                                           |
|  2. TRANSMISSION      Propagation along primary afferents to spinal dorsal horn (Laminae I & II      |
|                      Substantia Gelatinosa). Decussation in anterior white commissure; ascent via    |
|                      Spinothalamic Tract to VPL thalamus and sensory cortex.                         |
|                                          |                                                           |
|                                          v                                                           |
|  3. MODULATION       Descending inhibitory pathways originating from Periaqueductal Gray (PAG)       |
|                      and Rostral Ventromedial Medulla (RVM) release Serotonin (5-HT),                |
|                      Norepinephrine (alpha-2 receptors), and Endogenous Opioids.                     |
|                                          |                                                           |
|                                          v                                                           |
|  4. PERCEPTION       Conscious awareness and affective-emotional integration of pain within the     |
|                      Somatosensory Cortex (S1/S2), Insular Cortex, and Anterior Cingulate Cortex.    |
+------------------------------------------------------------------------------------------------------+

The Four Phases of Nociception

1. Transduction: Noxious mechanical, thermal, or chemical stimuli are converted into electrical action potentials at peripheral free nerve endings of primary afferent nociceptors:
   • $A\delta$ Fibers: Thinly myelinated, medium diameter ($2 - 5\text{ }\mu\text{m}$), conduction velocity $5 - 30\text{ m/s}$. Mediate rapid, sharp, well-localized "first pain."
   • C Fibers: Unmyelinated, small diameter ($0.4 - 1.2\text{ }\mu\text{m}$), slow conduction velocity $0.5 - 2\text{ m/s}$. Mediate delayed, dull, aching, burning "second pain."
   • Transduction Receptors: Transient Receptor Potential Vanilloid 1 (TRPV1, activated by heat $>43^\circ\text{C}$, protons $H^+$, capsaicin); Acid-Sensing Ion Channels (ASIC); Purinergic P2X/P2Y receptors (activated by extracellular ATP released from ruptured cells); and voltage-gated sodium channels ($\text{Na}_V1.7, \text{Na}_V1.8, \text{Na}_V1.9$).
   • The Inflammatory Soup: Tissue trauma releases a potent cocktail of algogenic substances: bradykinin, prostaglandin $E_2$ ($PGE_2$), substance P, calcitonin gene-related peptide (CGRP), histamine, serotonin ($5\text{-HT}$), protons ($H^+$), leukotrienes, and nerve growth factor (NGF).
2. Transmission: Action potentials travel along primary afferent neurons whose cell bodies reside in the dorsal root ganglion (DRG), entering the spinal dorsal horn via the tract of Lissauer. They terminate in Rexed Lamina I (marginal zone) and Rexed Lamina II (substantia gelatinosa). The presynaptic terminals release excitatory neurotransmitters:
   • Glutamate: Rapid excitation acting on postsynaptic $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors.
   • Substance P & CGRP: Neuropeptides acting on Neurokinin-1 (NK-1) and CGRP receptors, producing slow, sustained excitatory postsynaptic potentials.
   • Second-order projection neurons decussate obliquely across the anterior white commissure of the spinal cord within 1 to 2 segments and ascend in the contralateral anterolateral quadrant as the Spinothalamic Tract (STT):
     • Neospinothalamic Tract: Projects directly to the ventral posterolateral (VPL) nucleus of the thalamus, relaying to primary and secondary somatosensory cortices ($S1, S2$) to decode sensory-discriminative properties (location, intensity, duration).
     • Paleospinothalamic Tract: Projects to the medial thalamus, periaqueductal gray, reticular formation, and limbic structures, mediating affective-motivational and autonomic responses.
3. Modulation: Endogenous pain suppression occurs through descending inhibitory pathways originating from the Periaqueductal Gray (PAG) in the midbrain and the Rostral Ventromedial Medulla (RVM) (including the nucleus raphe magnus). These bulbospinal tracts project down the dorsolateral funiculus to synapse on primary afferents and interneurons in the dorsal horn, releasing:
   • Norepinephrine: Activates presynaptic and postsynaptic $\alpha_2$-adrenoceptors, inhibiting calcium influx and hyperpolarizing dorsal horn neurons.
   • Serotonin ($5\text{-HT}$): Activates inhibitory interneurons via distinct 5-HT receptor subtypes.
   • Endogenous Opioid Peptides: $\beta$-endorphin (acts on $\mu$-receptors), met- and leu-enkephalin (acts on $\delta$-receptors), and dynorphin (acts on $\kappa$-receptors), hyperpolarizing neurons by opening inward-rectifying potassium channels and closing voltage-gated calcium channels.
4. Perception: The conscious subjective experience of pain arising from extensive reciprocal connections between the thalamus, somatosensory cortex, anterior cingulate cortex (ACC) (affective distress), insular cortex (interoception and autonomic integration), and prefrontal cortex.

Peripheral vs. Central Sensitization

• Peripheral Sensitization: Prolonged exposure to the "inflammatory soup" phosphorylates transducer channels (TRPV1, $\text{Na}_V1.8$). This lowers the activation threshold and increases the firing rate of primary nociceptors, producing primary hyperalgesia (exaggerated pain sensitivity strictly confined to the zone of primary tissue trauma).
• Central Sensitization and "Wind-Up": Repetitive, sustained high-frequency C-fiber firing triggers continuous glutamate and substance P release into the dorsal horn. Sustained membrane depolarization removes the resting, voltage-dependent magnesium ion ($Mg^{2+}$) block from the pore of the N-methyl-D-aspartate (NMDA) receptor. Calcium ($Ca^{2+}$) pours into the postsynaptic neuron, activating protein kinase C (PKC), calcium/calmodulin-dependent protein kinase II (CaMKII), and neuronal nitric oxide synthase (nNOS). This induces long-term potentiation (LTP) of pain transmission:
  • Clinical Hallmarks:
    • Secondary Hyperalgesia: Increased pain sensitivity in undamaged normal tissues surrounding the primary surgical wound.
    • Allodynia: Perception of pain provoked by normally innocuous stimuli (e.g., light brush of clothing or bedsheets, mediated by low-threshold $A\beta$ fibers misinterpreting touch as pain due to dorsal horn hyper-responsiveness).
  • Ketamine's Role: Subanaesthetic ketamine is a non-competitive antagonist of open NMDA receptors, directly blocking the $Ca^{2+}$ pore to abort "wind-up" and reverse central sensitization.

---

2. The Multimodal Analgesia Paradigm

Multimodal analgesia combines two or more analgesic classes with different mechanisms of action and discrete target receptors within the peripheral and central nervous systems. Rational combinations produce additive or synergistic analgesia while lowering individual drug doses, achieving an opioid-sparing effect of $30 - 50\%$ and drastically curbing Opioid-Related Adverse Events (ORAEs):

• Postoperative nausea and vomiting (PONV)
• Paralytic ileus and delayed return of bowel motility
• Sedation and life-threatening respiratory depression
• Urinary retention and pruritus
• Long-term physical dependence and opioid-induced hyperalgesia (OIH)

---

3. Systemic Non-Opioid Pharmacological Modalities

+-----------------------------------------------------------------------------------------------------+
|                                 MULTIMODAL NON-OPIOID PHARMACOTHERAPY                               |
|                                                                                                     |
|  Drug Class        Agent & Dosing           Primary Mechanism            Key Traps & Constraints    |
|  ----------------  -----------------------  ---------------------------  -------------------------  |
|  Paracetamol       1 g IV/oral q6h          Central COX inhibition;      Max 4 g/24h; reduce in     |
|                    (scheduled baseline)     AM404 active metabolite;     severe hepatic failure or  |
|                                             cannabinoid CB1/TRPV1        chronic malnutrition       |
|                                                                                                     |
|  NSAIDs / COX-2    Ketorolac 15-30 mg IV;   Peripheral & central COX     Avoid in CKD, hypovolemia, |
|  Inhibitors        Celecoxib 200-400 mg PO  inhibition; blocks PGE2;     active peptic ulcers, GI   |
|                                             reduces opioid use 30-40%    bleed, bone fusion surgery |
|                                                                                                     |
|  IV Lidocaine      1-1.5 mg/kg bolus, then  Voltage-gated Na+ blockade;  ALLEGRO 2025: no ileus gain|
|  Infusion          1.5-2 mg/kg/h IV         anti-inflammatory; modest    toxic > 5 mcg/mL; avoid    |
|                                             opioid-sparing effect        concurrent regional blocks |
|                                                                                                     |
|  Low-Dose          0.25-0.5 mg/kg bolus,    Non-competitive NMDA         Inhibits central wind-up;  |
|  Ketamine          then 0.1-0.25 mg/kg/h    receptor channel blocker     ideal for opioid-tolerant; |
|                                                                          minimal psychomimetic dose |
|                                                                                                     |
|  Dexamethasone     4 - 8 mg IV at induction Inhibits phospholipase A2;   Dual anti-PONV and opioid  |
|                                             suppresses cytokines         sparing; mild hyperglycemia|
+-----------------------------------------------------------------------------------------------------+

Paracetamol (Acetaminophen)

• Mechanisms: Central inhibition of cyclooxygenase (COX-1, COX-2, and putative COX-3/COX-1b splice variants); active central metabolite $N$-arachidonoylphenolamine (AM404) stimulates cannabinoid $CB_1$ receptors and inhibits cellular anandamide reuptake; reinforces descending bulbospinal serotonergic pathways.
• Dosing & Clinical Role: Administered as a scheduled baseline: $1\text{ g}$ IV or oral every 6 hours (maximum $4\text{ g/24h}$ in adults $> 50\text{ kg}$; reduced to $2 - 3\text{ g/24h}$ in severe hepatic impairment, malnutrition, or chronic alcoholism).

NSAIDs and Selective COX-2 Inhibitors

• Mechanisms: Inhibit cyclooxygenase enzymes, preventing the conversion of arachidonic acid to prostaglandin $H_2$ ($PGH_2$), blunting $PGE_2$ and $PGI_2$ synthesis to eliminate peripheral nociceptive sensitization and spinal inflammatory wind-up. Reduces opioid consumption by $30 - 40\%$.
• Non-Selective NSAIDs vs. Selective COX-2 Inhibitors:
  • Non-selective (Ketorolac, Ibuprofen, Diclofenac): Inhibit both COX-1 (constitutive, produces cytoprotective gastric mucus and thromboxane $A_2$ in platelets) and COX-2 (inducible by cytokines at surgical injury sites). Inhibit platelet aggregation; increase surgical bleeding risk.
  • Selective COX-2 Inhibitors (Celecoxib, Parecoxib): Selectively inhibit inducible COX-2, leaving platelet COX-1 uninhibited (zero impact on platelet aggregation and bleeding time; reduced gastrointestinal ulceration risk).
• Contraindications and Organ Toxicities:
  • Renal: Prostaglandins ($PGE_2, PGI_2$) maintain vasodilatory perfusion of afferent renal arterioles in hypovolemic or compromised states. NSAIDs precipitate acute kidney injury (prerenal vasoconstriction and acute tubular necrosis) in hypovolemia, dehydration, or pre-existing chronic kidney disease ($GFR < 30\text{ mL/min}$). Avoid in unstable hemodynamics.
  • Bone Healing: Prostaglandins stimulate osteoblastic differentiation. NSAIDs are controversial or contraindicated in high-risk spinal fusion surgery or non-union fracture repair.

Intravenous Lidocaine Infusion

• Mechanisms: Systemic local anaesthetic infusion blocks open and inactivated voltage-gated sodium channels ($\text{Na}_V$) in primary afferents; suppresses aberrant ectopic neural discharges; attenuates inflammatory cytokine cascade release (IL-1, IL-6, TNF-$\alpha$); inhibits neutrophil priming and lysosomal enzyme degranulation.
• Dosing Regimen: Intravenous loading bolus of $1.0 - 1.5\text{ mg/kg}$ (based on ideal body weight) administered over $10 - 15\text{ minutes}$ at induction of anaesthesia, followed by a continuous infusion of $1.5 - 2.0\text{ mg/kg/h}$ maintained intraoperatively and continued for up to $24 - 48\text{ hours}$ postoperatively.
• Clinical Indications & Evidence: Earlier small trials and meta-analyses suggested faster return of bowel function after colorectal surgery. However, the large multicentre ALLEGRO trial (Paterson et al., JAMA 2025) found that perioperative IV lidocaine did not improve the return of gastrointestinal function at 72 hours compared with placebo, so routine use to prevent ileus is no longer supported. It may still be considered as an opioid-sparing adjunct when regional techniques are not possible.
• Safety & Toxicity Monitoring: Therapeutic plasma concentrations range between $1.5 - 5.0\text{ }\mu\text{g/mL}$. Toxicity ($> 5.0\text{ }\mu\text{g/mL}$) presents sequentially with perioral paresthesia, metallic taste, tinnitus, lightheadedness, slurred speech, visual disturbances, tremors, seizures, and cardiovascular collapse. Critical Safety Rule: Strictly avoid concurrent therapeutic continuous peripheral nerve blocks or high-volume regional local anaesthetic infiltrations while systemic IV lidocaine is infusing, as the cumulative local anaesthetic dose increases the risk of LAST.

Low-Dose Ketamine

• Mechanisms: Non-competitive NMDA receptor open-channel antagonist. Blocks the calcium pore, prevents spinal dorsal horn wind-up, attenuates acute opioid tolerance, and prevents opioid-induced hyperalgesia (OIH).
• Dosing: IV bolus of $0.25 - 0.5\text{ mg/kg}$ at induction, followed by an infusion of $0.1 - 0.25\text{ mg/kg/h}$ ($2 - 4\text{ }\mu\text{g/kg/min}$) discontinued at skin closure or continued for $24\text{ hours}$.
• Target Population: Highly effective in major painful surgeries (thoracotomy, major spinal reconstruction, upper abdominal surgery) and essential in opioid-tolerant chronic pain patients.

Alpha-2 Adrenoceptor Agonists

• Clonidine & Dexmedetomidine: Highly selective $\alpha_2$-agonists acting on presynaptic and postsynaptic receptors in the locus coeruleus and substantia gelatinosa. Inhibit substance P release and blunt sympathetic outflow, providing "cooperative sedation" without respiratory depression, while reducing postoperative opioid requirements. Side effects include dose-dependent bradycardia, hypotension, and dry mouth.

Dexamethasone

• Mechanisms: Glucocorticoid receptor activation inhibits phospholipase $A_2$ via lipocortin induction, halting arachidonic acid liberation and cytokine transcription.
• Dosing: $4 - 8\text{ mg}$ IV administered at induction. Provides potent, dual-purpose PONV prophylaxis and sustained opioid-sparing somatic analgesia, while prolonging the duration of peripheral nerve blocks when administered intravenously or perineurally.

---

4. Patient-Controlled Analgesia (PCA) Regimens and Safety

Patient-Controlled Analgesia allows patients to self-administer small, pre-programmed intravenous doses of an opioid on demand. Peak efficacy and patient safety require precise parameter programming:

Sedation Monitoring: The Earliest Predictor of Toxicity

Respiratory rate alone is an insensitive and dangerously late indicator of opioid-induced respiratory depression. Arterial hypercapnia and somnolence precede bradypnea. Sedation scoring using standardized scales (such as the Pasero Opioid-Induced Sedation Scale - POSS) must be monitored regularly:

• S: Sleep, easy to arouse (acceptable).
• 1: Awake and alert (acceptable).
• 2: Slightly drowsy, easily aroused (acceptable).
• 3: Frequently drowsy, drifts off to sleep during conversation (UNACCEPTABLE; stop PCA immediately, administer oxygen, notify physician, decrease opioid dose by $50\%$).
• 4: Somnolent, minimal or no response to verbal/physical stimulation (EMERGENCY; stop PCA, initiate immediate bag-mask ventilation, administer incremental titrated IV naloxone $40 - 100\text{ }\mu\text{g}$ until awake).

---

5. Enhanced Recovery After Surgery (ERAS) Protocols

Enhanced Recovery After Surgery (ERAS) is an evidence-based, multimodal, multidisciplinary perioperative care pathway designed to blunt the surgical neuroendocrine stress response, preserve physiological organ reserve, minimize postoperative complications, and accelerate functional recovery.

                                  [ ERAS PERIOPERATIVE CONTINUUM ]
                                                 |
       +-----------------------------------------+-----------------------------------------+
       |                                         |                                         |
  [ PREOPERATIVE ]                          [ INTRAOPERATIVE ]                        [ POSTOPERATIVE ]
  - Preadmission counseling                 - Thoracic epidural (T8-T10 for open)     - Early oral fluids & nutrition
  - Smoking/alcohol cessation >= 4 wks      - Multi-plane fascial blocks (lap)          within 4 to 6 hours
  - Optimized nutritional status            - Multimodal opioid-sparing analgesia     - Scheduled non-opioid analgesia
  - Carbohydrate loading (clear liquids     - Goal-directed fluid therapy (GDFT)      - Early mobilization out of bed
    up to 2h pre-induction)                   using dynamic parameters (SVV/PPV)        on day of surgery (> 2h)
  - Avoidance of prolonged fasting          - Active warming (normothermia > 36°C)    - Early urinary catheter removal
  - Avoidance of mechanical bowel prep      - Avoidance of routine drains/NG tubes      (< 24-48 hours)

Core Elements Across the Perioperative Phases

1. Preoperative Phase:
   • Preadmission Education & Prehabilitation: Setting realistic expectations regarding pain, functional milestones, and discharge criteria.
   • Smoking and Alcohol Cessation: Minimum of 4 weeks prior to elective surgery to restore mucociliary clearance and immune function.
   • Carbohydrate Loading & Fasting Guidelines: Fasting from solid food for 6 hours; unrestricted ingestion of clear fluids containing complex carbohydrates (maltodextrin $800\text{ mL}$ evening prior, $400\text{ mL}$ up to 2 hours before induction). This transitions the patient from a catabolic, insulin-resistant fasting state into an anabolic, fed state, reducing postoperative insulin resistance by $50\%$, preserving skeletal muscle mass, and alleviating thirst, anxiety, and hunger.
   • Avoidance of Mechanical Bowel Preparation: Routine oral bowel preparation causes severe dehydration, electrolyte derangements, and mucosal inflammation, and is omitted in colonic surgery.
2. Intraoperative Phase:
   • Surgical Access & Technique: Laparoscopic or robotic minimally invasive surgery whenever feasible to minimize tissue trauma and cytokine release.
   • Neuraxial & Regional Analgesia: Low-thoracic epidural analgesia (T8 - T10) with low-dose local anaesthetic and lipophilic opioids for major open abdominal laparotomies; provides profound analgesia, blocks splanchnic sympathetic tone, and reduces ileus. For laparoscopic cases, multi-modal fascial plane blocks (TAP, ESP, rectus sheath) are favored.
   • Goal-Directed Fluid Therapy (GDFT): Restrictive or goal-directed balanced crystalloid administration utilizing dynamic stroke volume variation ($SVV$) or pulse pressure variation ($PPV$) guided by arterial waveform analysis or esophageal Doppler. Prevents both hypervolemia (which produces intestinal edema, impaired anastomotic healing, and pulmonary complications) and hypovolemia (renal hypoperfusion).
   • Maintenance of Normothermia: Active forced-air warming to maintain core temperature $> 36.0^\circ\text{C}$, preventing hypothermia-induced coagulopathy, surgical site infections, and shivering-induced myocardial strain.
   • Avoidance of Routine Nasogastric Tubes and Peritoneal Drains: Unnecessary NGTs increase atelectasis, aspiration, and pneumonia; prophylactic surgical drains do not prevent anastomotic leaks and hinder early ambulation.
3. Postoperative Phase:
   • Early Enteral Nutrition: Reintroduction of oral fluids and regular solid food within $4 - 6\text{ hours}$ postoperatively; stimulates coordinated gastrointestinal peristalsis and mucosal healing.
   • Early Ambulation: Mobilization out of bed into a chair on the day of surgery, progressing to walking $> 2 - 4\text{ hours/day}$ on postoperative day 1; prevents deep vein thrombosis, preserves skeletal muscle, and expands functional residual capacity ($FRC$).
   • Early Catheter Removal: Urinary Foley catheters removed within $< 24 - 48\text{ hours}$ postoperatively to reduce catheter-associated urinary tract infections (CAUTI) and unencumber patient mobility.
   • Proactive Multimodal PONV Prophylaxis: Routine dual- or triple-agent prophylaxis (dexamethasone $4 - 8\text{ mg}$, ondansetron $4\text{ mg}$, droperidol $0.625\text{ mg}$) tailored to Apfel risk scores.